Autoimmune encephalopathy with parasomnia and obstructive sleep apnea

Summary

Autoimmune encephalopathy with parasomnia and obstructive sleep apnea (MONDO:0018489) is a disease and 1 clinical trial. A subtype of autoimmune disorder of central nervous system — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		10	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	autoimmune encephalopathy with parasomnia and obstructive sleep apnea
Mondo ID	MONDO:0018489
Orphanet	420789
SNOMED CT	765751002
UMLS	C4707562
MedGen	1644256
GARD	0021749
Is cancer (heuristic)	no

Also known as: anti-IgLON5 disease · anti-IgLON5 syndrome

Disease family

This is a subtype of autoimmune disorder of central nervous system. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autoimmune disorder of central nervous system › autoimmune encephalopathy with parasomnia and obstructive sleep apnea

Related subtypes (7): multiple sclerosis, Miller Fisher syndrome, lymphocytic hypophysitis, autoimmune encephalitis, autoimmune optic neuritis, central nervous system lupus, autoimmune epilepsy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06131346	Not specified	UNKNOWN	Clinical Characterization and Outcome of Anti-IgLON5 Disease